Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Olema Pharmaceuticals, Inc. has received a consensus rating of "Moderate Buy" from six ratings firms, with five analysts recommending a buy and one a sell.
• The average 12-month price target for Olema Pharmaceuticals among analysts is $24.00, with HC Wainwright setting a target of $30.00.
• As of now, shares of Olema Pharmaceuticals are trading at $5.26, having a market capitalization of approximately $360.99 million.

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have received an average recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $24.00.

Several brokerages recently weighed in on OLMA. JPMorgan Chase & Co. increased their price objective on shares of Olema Pharmaceuticals from $28.00 to $29.00 and gave the company an "overweight" rating in a report on Thursday, August 14th. Citigroup increased their target price on shares of Olema Pharmaceuticals from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Tuesday, August 12th. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a report on Monday, April 28th. The Goldman Sachs Group cut their target price on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Oppenheimer cut their target price on shares of Olema Pharmaceuticals from $25.00 to $22.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th.

Institutional Trading of Olema Pharmaceuticals

A number of hedge funds have recently modified their holdings of OLMA. Ameritas Investment Partners Inc. lifted its stake in shares of Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company's stock worth $26,000 after buying an additional 2,168 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Olema Pharmaceuticals by 602.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company's stock worth $29,000 after purchasing an additional 5,866 shares in the last quarter. FNY Investment Advisers LLC raised its stake in Olema Pharmaceuticals by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock worth $42,000 after purchasing an additional 5,000 shares in the last quarter. Quarry LP acquired a new stake in Olema Pharmaceuticals in the 1st quarter worth about $45,000. Finally, Alpine Global Management LLC acquired a new stake in Olema Pharmaceuticals in the 1st quarter worth about $52,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Olema Pharmaceuticals Stock Performance

Olema Pharmaceuticals stock traded down $0.04 on Friday, reaching $5.39. 111,637 shares of the stock were exchanged, compared to its average volume of 874,352. The firm has a fifty day moving average price of $4.70 and a two-hundred day moving average price of $4.62. The stock has a market cap of $369.94 million, a PE ratio of -2.73 and a beta of 1.92. The company has a current ratio of 11.09, a quick ratio of 11.09 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals has a twelve month low of $2.86 and a twelve month high of $13.93.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). Sell-side analysts anticipate that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.